65,437 trials
Endometrial Neoplasms
Primary: Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)…
Peripheral Neuropathies
Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale
Prostate Cancer Metastatic
Primary: Number of Participants With Prostate Specific Antigen (PSA) >=50 Response — 5 Participants
Meningococcal Vaccine
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…
Psoriatic Arthritis
Primary: Percentage of Participants With American College of Rheumatology 50 (ACR50) Response — 6.8; 43.4 percentage of participants — p=<0.001
Pulmonary Artery Hypertension
Primary: Change From Baseline in Six Minute Walk Distance (Meters) — 414.5; 461.7; 448.9; 483.0 meters
Cutaneous Neurofibroma
Primary: Short Term Safety Profile - Adverse Events — 0; 20 Participants
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Peripheral Vascular Disease
Primary: Feasibility of Implementing Preoperative Guided Meditation — 15; 14 Participants
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) Recommended Dose of Pembrolizumab in Combination With Lead in Pembrolizumab and Afatinib Dimaleate — 40 mg
Breast Cancer
Primary: Functional Assessment of the Discussion Prioritization Tool (DPT) — 78.5 score on a scale
Cushings Disease
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability Profile of Pasireotide s.c. — 11; 13; 34; 54 Participants
Dental Caries in Children · Dental Caries Class II · Dental Caries
Primary: Interproximal Caries Zone of Radiolucency — 9; 7; 10; 12 Number of teeth
Allergy Drug · Allergic Reaction · Pediatric
Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants